Spikevax JN.1: Uses, Dosage & Side Effects

What Is Spikevax JN.1 and What Is It Used For?

Spikevax JN.1 is the 2024–2025 strain-updated formulation of Moderna's licensed mRNA COVID-19 vaccine. The earlier formulations of this product have been authorized in over 70 countries since late 2020, first under conditional or emergency-use authorization and later through full marketing authorization in the European Union, the United States, the United Kingdom, Canada, Japan and many other jurisdictions. The JN.1 update preserves the proven mRNA/lipid nanoparticle platform of the parent product but replaces the encoded spike sequence with one drawn from the Omicron JN.1 sub-lineage, which became globally dominant during late 2023 and 2024. Regulatory authorities including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada authorized the JN.1 update during mid-2024 following recommendations from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC).

Coronavirus disease 2019 (COVID-19) is an acute respiratory and multi-system infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since its emergence in late 2019, SARS-CoV-2 has caused hundreds of millions of confirmed cases and many millions of deaths worldwide. Although the absolute risk of severe disease has decreased over time as population immunity has accumulated through vaccination and natural infection, COVID-19 continues to cause a substantial burden of hospitalization, intensive-care admission, long COVID, and excess mortality, particularly among older adults, immunocompromised individuals, and people with chronic medical conditions. Ongoing viral evolution — most recently within the Omicron family of variants and their JN.1-descendant lineages (KP.2, KP.3, LB.1, XEC) — has progressively eroded the neutralizing antibody response generated by earlier vaccine formulations, which is why the vaccine composition is updated periodically.

The approved indication for Spikevax JN.1 is active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. In most national immunization programmes it is recommended primarily as a booster dose in people who have previously received one or more doses of any authorized COVID-19 vaccine, and as a primary-schedule product for those who have not yet been vaccinated or who are immunologically naïve. Priority groups for boosting typically include adults 65 years and older, residents of long-term care facilities, pregnant women, moderately to severely immunocompromised patients, healthcare workers, and people with chronic conditions such as diabetes, cardiovascular disease, chronic lung disease, chronic kidney disease, and morbid obesity. Although local recommendations differ slightly between countries, the underlying principle is the same: to maintain durable protection against severe COVID-19 disease.

Mechanistically, Spikevax JN.1 delivers a single-stranded, 5'-capped, nucleoside-modified messenger RNA (the active substance elasomeran) encapsulated in proprietary lipid nanoparticles (LNPs). The LNPs are composed of four lipid species (an ionizable cationic lipid, a PEG-lipid, a structural phospholipid, and cholesterol) that together protect the mRNA during storage and transport, allow it to cross the cell membrane, and release it into the cytoplasm. Once inside the cell, the mRNA is translated by host ribosomes to produce the full-length, pre-fusion stabilized spike glycoprotein of the SARS-CoV-2 JN.1 sub-lineage. The translated spike protein is processed and presented by antigen-presenting cells, triggering an adaptive immune response that generates neutralizing antibodies, memory B cells, and CD4+ and CD8+ T cells. Nucleoside modification (replacement of uridine with N1-methylpseudouridine) reduces innate immune detection of the mRNA and improves translation efficiency. Importantly, the mRNA is transient, does not enter the nucleus, and is rapidly degraded by normal cellular enzymes within days of injection.

The JN.1 update was selected because the JN.1 sub-lineage (a descendant of BA.2.86) accumulated additional spike mutations, most notably the L455S substitution, that conferred substantial escape from the neutralizing antibody responses elicited by earlier vaccine formulations (ancestral Wuhan-Hu-1, bivalent BA.1, bivalent BA.4/BA.5, monovalent XBB.1.5). Pre-clinical and clinical immunogenicity studies of JN.1-adapted mRNA vaccines demonstrated substantially higher neutralizing antibody titres against JN.1 and its descendants (including KP.2, KP.3, LB.1 and XEC sub-lineages) compared with XBB.1.5-based vaccines, supporting the rationale for the strain update. In parallel, T-cell responses — which are generally more conserved across variants than antibody responses — are also re-stimulated and broadened.

In clinical terms, the intended effects of Spikevax JN.1 are:

• Primary benefit: Reduce the risk of severe COVID-19, defined as hospitalization, admission to an intensive care unit, requirement for supplemental oxygen or mechanical ventilation, and death.
• Secondary benefit: Reduce the probability of symptomatic SARS-CoV-2 infection, particularly during the first 3–6 months after immunization when neutralizing antibody titres are highest.
• Tertiary benefit: Contribute to reducing the risk of post-acute sequelae of COVID-19 (long COVID), and blunt the impact of seasonal waves on acute-care services.

Vaccine effectiveness evolves as new variants emerge and as post-vaccination time elapses. Real-world test-negative case-control studies following earlier (XBB.1.5-based) formulations demonstrated relative vaccine effectiveness of approximately 40–55% against symptomatic COVID-19 and 60–75% against COVID-19 hospitalization in adults within the first 3–4 months after vaccination, with waning thereafter. Post-licensure effectiveness data for JN.1-adapted vaccines indicate similar or improved protection against the JN.1-descendant variants dominant since late 2024. It is important to recognize that, as with influenza vaccines, perfect prevention of infection is not achievable; the primary public-health goal is to protect against severe disease.

What Should You Know Before Taking Spikevax JN.1?

Contraindications

Spikevax JN.1 must not be administered in the following situations. It must not be given to individuals with a documented history of anaphylaxis or other severe immediate allergic reaction to a previous dose of any mRNA COVID-19 vaccine (Spikevax or Comirnaty), or to any component of this vaccine. The principal allergen of concern is polyethylene glycol 2000 (PEG-2000), which is present in the lipid nanoparticle formulation and has cross-reactivity with polysorbate 80 in certain individuals. Anaphylaxis to other injectable medicines containing PEG or to cosmetic/pharmaceutical products containing PEG should be reviewed carefully before vaccination, preferably in consultation with an allergist.

Persons who develop anaphylaxis after a first dose of an mRNA COVID-19 vaccine should not receive a second dose of the same or a different mRNA vaccine; in such cases, alternative vaccine platforms (for example a protein-subunit or adjuvanted recombinant protein vaccine) may be considered, depending on local availability and specialist assessment. A history of mild local or systemic reactogenicity after a previous dose is not a contraindication and does not preclude further doses.

Warnings and Precautions

Vaccination should be postponed in individuals with an acute, moderate-to-severe febrile illness. Minor illnesses such as uncomplicated upper respiratory tract infections or low-grade fever are not a reason to delay vaccination. The benefit of timely vaccination usually outweighs the theoretical risk of masking or complicating the assessment of an ongoing illness, but clinical judgement should be exercised.

Myocarditis and pericarditis have been reported following vaccination with mRNA COVID-19 vaccines. Observational data from multiple national surveillance systems (VAERS in the United States, EudraVigilance in the European Union, the MHRA Yellow Card Scheme in the United Kingdom) indicate an elevated risk, estimated at approximately 3–12 additional cases per 100,000 doses, with the highest risk in adolescent and young adult males aged 12–29 years within 14 days after the second or subsequent dose. Most reported cases have been mild, have responded promptly to standard treatment (non-steroidal anti-inflammatory drugs, rest, occasionally corticosteroids), and have resolved without long-term sequelae on clinical and cardiac magnetic resonance imaging (CMR) follow-up. The risk of myocarditis after SARS-CoV-2 infection itself is higher than after vaccination across all age groups. Vaccine recipients should seek prompt medical attention if they develop chest pain, shortness of breath, palpitations, or feelings of a rapid or fluttering heartbeat in the weeks following vaccination.

Anaphylaxis has been reported very rarely after mRNA COVID-19 vaccines, at a rate of approximately 2–11 cases per million doses. For this reason, Spikevax JN.1 must be administered by healthcare professionals trained to recognize and treat anaphylaxis, and vaccine recipients are typically observed for 15 minutes after injection (30 minutes if they have a relevant allergy history). Anaphylaxis equipment, including intramuscular epinephrine (adrenaline) auto-injectors or ampoules, must be available at the point of care.

Syncope (fainting) can occur in association with any injectable vaccine, particularly in adolescents and young adults, usually as a vasovagal response to the injection rather than to the vaccine itself. Procedures to prevent injury from fainting should be in place (supervised observation, seated or supine injection if appropriate).

Bleeding disorders and anticoagulant therapy are not contraindications but require a careful injection technique, the use of a finer-gauge needle, prolonged pressure at the injection site after the dose, and clear documentation. Spikevax JN.1 can be administered to individuals receiving warfarin, direct oral anticoagulants, antiplatelet drugs, or low-molecular-weight heparin following national guidance for intramuscular injections in these groups.

Immunocompromised individuals — including solid-organ transplant recipients, people with haematological malignancies, those receiving anti-CD20 therapies (such as rituximab, ocrelizumab), high-dose corticosteroids, calcineurin inhibitors or strong immunosuppressive chemotherapy — may mount a reduced immune response to vaccination. These patients are typically offered additional doses and may benefit from timing considerations around their immunosuppressive therapy (for example, vaccination at least 2–4 weeks before or several months after anti-CD20 therapy where possible). Vaccination is not contraindicated but should be planned in collaboration with the treating specialist.

As with any vaccine, Spikevax JN.1 may not fully protect every recipient. Immunization does not replace adherence to other public-health recommendations (ventilation, respirator-grade masking in high-risk situations, testing when symptomatic, isolation when infectious) that remain important, particularly for high-risk individuals and during periods of intense transmission.

Pregnancy and Breastfeeding

COVID-19 during pregnancy is associated with a clinically important increase in the risk of severe maternal illness, intensive-care admission, invasive ventilation, preterm birth, stillbirth, and poor neonatal outcomes. For this reason, vaccination during pregnancy is recommended by the WHO, the U.S. Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control (ECDC), the UK Joint Committee on Vaccination and Immunisation (JCVI), and most national immunization authorities at any gestational age, including in the first trimester.

Safety data from international pregnancy registries (v-safe COVID-19 Vaccine Pregnancy Registry, the UKHSA COVID-19 Vaccines Surveillance in Pregnancy, the Canadian Surveillance of COVID-19 in Pregnancy) now cover several hundred thousand vaccinated pregnancies with earlier versions of Spikevax and have not identified a safety signal for miscarriage, stillbirth, preterm birth, congenital anomalies, low birthweight, or neonatal death. The JN.1-adapted formulation uses the same platform and excipients as prior versions, and therefore the existing safety evidence is considered directly relevant. Vaccination also confers passive immunity on the newborn through transplacental antibody transfer, reducing the infant's risk of severe COVID-19 during the first months of life when they are not yet eligible for vaccination.

Breastfeeding is not a contraindication. mRNA is not expected to reach breast milk in meaningful amounts, and observational studies have demonstrated that antibodies produced in the vaccinated mother are transferred through breast milk and may contribute to protection of the infant.

Effects on Driving and Use of Machines

Spikevax JN.1 has no direct effect on the ability to drive or operate machinery. However, some vaccine recipients experience fatigue, headache, myalgia, dizziness, or occasional fever in the first 24–48 hours after vaccination, which could temporarily impair concentration and reaction time. If these symptoms are present, driving or operation of machinery should be avoided until they have resolved.

Children and Adolescents

Spikevax JN.1 is authorized for use from 6 months of age in most jurisdictions, with a reduced dose of 25 µg (0.25 mL) recommended for children aged 6 months to 11 years. National recommendations on whether and when to vaccinate healthy children in this age range vary — some countries recommend routine vaccination of all children, others restrict the recommendation to children at increased risk of severe COVID-19 or with household members at risk. Parents and caregivers should consult their national immunization schedule or their family physician/paediatrician for the most current guidance. The safety profile in children is generally similar to that in adults, with fewer systemic events reported in younger children.

Older Adults

Older adults, particularly those 65 years and older, are at the highest risk of severe COVID-19 and therefore derive the greatest absolute benefit from vaccination. No dose adjustment is required based on age alone, and Spikevax JN.1 may be co-administered with the seasonal influenza vaccine and other age-appropriate vaccines (see the dedicated interaction section below). Although the immune response in very old adults may be lower than in younger populations, clinical effectiveness against severe outcomes remains substantial and is the main rationale for vaccination in this age group.

Hepatic and Renal Impairment

Because Spikevax JN.1 acts locally at the injection site and the small amounts of mRNA and lipid excipients are degraded via normal intracellular processes, no dose adjustment is required for patients with hepatic or renal impairment. Safety and immunogenicity have not been studied specifically in patients on dialysis or with advanced cirrhosis in dedicated trials, but extensive post-marketing experience with the platform across these populations has not raised specific safety concerns.

How Does Spikevax JN.1 Interact with Other Drugs?

Because Spikevax JN.1 is an injectable vaccine that acts locally at the injection site and through antigen presentation to the immune system, it does not undergo classical hepatic metabolism (cytochrome P450), renal excretion, or systemic distribution in the pharmacokinetic sense that applies to oral or parenteral small-molecule drugs. Consequently, traditional pharmacokinetic drug–drug interactions (for example with CYP3A4 inhibitors or inducers) are not relevant. The clinically important interactions involve: (1) medications that modulate the immune response and may reduce vaccine effectiveness, (2) drugs that increase bleeding risk at the injection site, (3) concomitant administration of other vaccines, and (4) specific antiviral or immune-based therapies for COVID-19.

Major Interactions and Considerations

Immunosuppressive and immunomodulatory therapies can blunt the antibody and T-cell response to Spikevax JN.1. The magnitude of the effect depends on the drug class, dose, duration, and timing relative to vaccination. Particularly relevant are B-cell-depleting agents (anti-CD20 antibodies such as rituximab, ocrelizumab, obinutuzumab, and ofatumumab), which can reduce humoral responses for 6–12 months after administration. Patients receiving these therapies should discuss optimal timing with their specialist; vaccination at least 4 weeks before the next cycle, or 4–6 months after the last dose, typically gives the best immunological response. High-dose corticosteroids (for example prednisolone ≥ 20 mg/day or equivalent for ≥ 14 days), calcineurin inhibitors, JAK inhibitors, mycophenolate mofetil, azathioprine, and cytotoxic chemotherapy can all reduce vaccine response but should not prevent vaccination. Additional doses are routinely offered to these patients.

Anticoagulant and antiplatelet therapy does not contraindicate intramuscular vaccination but requires a careful technique to minimize haematoma formation. A 23–25G needle, a single firm injection, and at least 2 minutes of direct pressure after removal of the needle are recommended. Warfarin-treated patients with a stable INR within the therapeutic range can safely receive intramuscular vaccines. Direct oral anticoagulants (DOACs), low-molecular-weight heparin, fondaparinux, and antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) do not need to be interrupted for vaccination.

Other vaccines can usually be co-administered with Spikevax JN.1 at separate injection sites. Co-administration with the seasonal influenza vaccine, including high-dose and adjuvanted formulations, is recommended in many countries to improve uptake of both vaccines and has been evaluated in dedicated clinical studies. Co-administration with RSV vaccines, pneumococcal vaccines, and routine childhood vaccines is also generally acceptable. A small additive increase in reactogenicity (mainly local injection-site pain and mild fatigue) has been observed when vaccines are co-administered, but immunogenicity is not meaningfully compromised. National immunization authorities will specify any age- or product-specific precautions.

Recently administered monoclonal antibodies or convalescent plasma directed against SARS-CoV-2 can theoretically bind the vaccine antigen and reduce the immune response. In practice, current WHO, CDC and ECDC guidance does not mandate delaying Spikevax JN.1 after passive immunization with antibodies no longer retaining activity against circulating variants, but the treating clinician should consider the agent, the dose, and the expected half-life when planning timing.

Minor or Theoretical Interactions

Routine over-the-counter medicines, including analgesics (paracetamol), antihistamines, proton-pump inhibitors, statins, antihypertensives (ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers), and oral hypoglycaemic agents do not interact with Spikevax JN.1 in any clinically significant way and should be continued as usual. Complementary therapies and supplements (vitamin D, vitamin C, zinc, probiotics) have not been shown to meaningfully improve or impair vaccine response and can be continued at the patient's discretion.

Prophylactic use of paracetamol or NSAIDs before vaccination to pre-empt fever or soreness is generally not recommended because small studies have suggested a modest reduction in antibody titres with prophylactic antipyretic use. These medicines can, however, be used after vaccination to treat symptoms that develop.

Overall, the single most important principle is open communication: vaccine recipients should inform the vaccinating healthcare professional about all current prescription and over-the-counter medications, supplements, and recent vaccinations or receipt of monoclonal antibodies, so that any clinically relevant considerations can be addressed before administration.

What Is the Correct Dosage of Spikevax JN.1?

Spikevax JN.1 is a strain-updated COVID-19 mRNA vaccine that is dosed by fixed volume rather than by patient body weight or body surface area. In most national immunization programmes, it is administered as a single dose per immunization season — usually in the autumn, timed to precede the annual winter wave of respiratory infections. A minority of moderately to severely immunocompromised individuals may receive additional doses. Dosing recommendations are harmonized across major regulatory authorities (EMA, FDA, MHRA, Health Canada) with minor national variations.

Adults and Adolescents (12 Years and Older)

Children (6 Months to 11 Years of Age)

Moderately to Severely Immunocompromised Individuals

Older Adults

Pregnancy and Breastfeeding

Hepatic or Renal Impairment

Missed Dose

If an additional or scheduled dose of Spikevax JN.1 is missed, it should be administered as soon as practical. There is no need to restart the vaccine series or to shorten the subsequent interval. The WHO and national immunization authorities emphasize that a delayed dose is preferable to a missed dose. Most vaccination programmes allow considerable flexibility in timing (intervals of 3, 6, or 12 months are common for different age and risk groups).

Overdose

Data on overdose (inadvertent administration of more than the recommended volume) with Spikevax JN.1 are limited to isolated case reports with earlier formulations. In those cases, recipients generally experienced a more pronounced but self-limiting reactogenicity profile (injection-site pain, fatigue, headache, myalgia, and in some cases short-lived fever) without specific systemic toxicity. There is no specific antidote; management is symptomatic with paracetamol, hydration, and close observation. Any overdose event should be reported to the manufacturer and to the national pharmacovigilance authority.

Administration Procedure

Spikevax JN.1 is supplied as a dispersion for injection in multi-dose or single-dose vials. Prior to use, the vial should be gently swirled — not shaken vigorously — to ensure homogeneous distribution of the lipid nanoparticles. The suspension should appear white to off-white and may contain white or translucent product-related particulates; coloured particles, foreign particulates, or clumps are unacceptable and the vial should be discarded. Each dose is drawn up into a syringe with a suitable needle (typically 23–25G) and administered intramuscularly in the deltoid muscle of the upper arm (or the anterolateral thigh in infants). Aspiration before injection is not recommended for intramuscular vaccines in general.

Duration of Effect and Revaccination

Neutralizing antibody titres peak approximately 4 weeks after vaccination and decline gradually thereafter, with a half-life of roughly 2–4 months during the first year. T-cell responses, including cross-reactive responses against emerging variants, are more durable. Clinical effectiveness against severe disease is substantial for at least 4–6 months after a booster and then wanes, particularly in older and immunocompromised individuals. For this reason, national immunization authorities typically recommend annual (or, for high-risk groups, biannual) revaccination with the most recent strain-updated formulation. The specific interval and eligibility criteria are periodically reviewed in response to circulating variants and epidemiological trends.

What Are the Side Effects of Spikevax JN.1?

Like all vaccines and medicines, Spikevax JN.1 can cause side effects, although not everybody experiences them. Reactogenicity (the expected, transient inflammatory response to an immunization) reflects the activation of the immune system by the vaccine antigen, and a robust but transient reaction is usually a sign that the vaccine is working as intended. Most events resolve within a few days and can be managed with simple measures (rest, fluids, paracetamol for fever or pain). Serious adverse events are rare, and the overall benefit–risk balance has been assessed as favourable by the EMA, FDA, MHRA, Health Canada, and the WHO Global Advisory Committee on Vaccine Safety (GACVS).

The frequency categories below follow the MedDRA convention used in the European Summary of Product Characteristics: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10 000 to < 1/1000), very rare (< 1/10 000), and not known (cannot be estimated from available data). Frequencies are drawn from the pooled clinical-trial dataset of Spikevax and its strain-updated variants and from post-authorization surveillance of hundreds of millions of administered doses.

Injection-site and systemic reactogenicity. Pain at the injection site is the most frequently reported reaction, typically beginning within hours of vaccination, peaking on the day after the injection, and resolving within 2–3 days. Fatigue, headache, myalgia, and chills are more common in younger adults than in older adults, and in people previously infected or vaccinated than in those receiving their first dose. A small minority of recipients develop delayed injection-site reactions 7–10 days after vaccination (often called “COVID arm”), with localized redness, warmth, itching, and mild swelling that resolves spontaneously over several days; this is not a contraindication to subsequent doses.

Lymphadenopathy. Axillary lymph node swelling on the side of the injection is expected and represents a normal activation of the draining lymph nodes. It is usually mild, unilateral, and transient (resolving within 1–2 weeks). Women scheduled for routine mammography are generally advised to delay screening for 4–6 weeks after vaccination or to have the contralateral arm injected to avoid imaging interpretation difficulties.

Myocarditis and pericarditis. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the pericardium) have been observed at a higher-than-background rate after mRNA COVID-19 vaccines, most often in adolescent and young adult males and typically within 14 days after the second or a subsequent dose. Observational estimates converge around 3–12 excess cases per 100,000 doses in this subgroup, with much lower rates in older adults and in females. The majority of reported cases are mild, present with chest pain, palpitations, shortness of breath or fatigue, and respond promptly to rest, non-steroidal anti-inflammatory drugs and, occasionally, colchicine or corticosteroids. Clinical outcomes are usually favourable, but longer-term cardiac magnetic resonance follow-up is recommended in some guidelines. Importantly, the incidence of myocarditis following SARS-CoV-2 infection itself is several times higher than after vaccination across all age groups, reinforcing the favourable benefit–risk balance.

Anaphylaxis. Anaphylaxis has been reported very rarely after mRNA COVID-19 vaccines, at approximately 2–11 cases per million doses. Most cases begin within 15 minutes of injection and respond promptly to intramuscular adrenaline. Vaccination must therefore be carried out in a setting with appropriate resuscitation equipment and trained staff. Individuals with a prior history of anaphylaxis to an mRNA vaccine or to a component of the vaccine should not receive Spikevax JN.1.

Menstrual changes. Short-term menstrual changes (heavier bleeding, earlier or later onset of the menstrual cycle, spotting) have been reported after COVID-19 vaccines, including mRNA products. Large population-based studies, including pooled analyses of cycle-tracking applications, have demonstrated small, transient cycle-length changes that typically resolve within one or two cycles. These observations prompted updates to the product information in several jurisdictions, emphasizing that such changes are generally self-limiting. If menstrual changes are persistent or severe, medical evaluation is appropriate to exclude other causes.

Delayed injection-site reactions. A delayed injection-site reaction (sometimes called “COVID arm”) can appear 5–14 days after a dose of mRNA vaccine and is characterized by localized redness, swelling, warmth, and itching at or near the deltoid injection site. It is a T-cell-mediated hypersensitivity and resolves spontaneously over several days, typically with topical corticosteroids or oral antihistamines for symptom management. It is not a contraindication to further doses.

Reporting Side Effects

If you experience any side effects, talk to your healthcare provider, pharmacist, or vaccinator. Reporting suspected adverse events is an essential part of post-authorization safety surveillance and contributes to continuously refining the benefit–risk profile of COVID-19 vaccines. In the European Economic Area, reports can be submitted via the national pharmacovigilance system (for example the MHRA Yellow Card Scheme in the United Kingdom, ANSM in France, or the BfArM/Paul-Ehrlich-Institut in Germany). In the United States, the Vaccine Adverse Event Reporting System (VAERS) is operated jointly by the FDA and CDC. In Canada, adverse events can be reported to the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). Reports can be submitted by the vaccinated individual, a family member, a carer, or a healthcare professional.

How Should You Store Spikevax JN.1?

As an mRNA-lipid nanoparticle product, Spikevax JN.1 is sensitive to temperature and handling. Its storage, transport, and handling are the responsibility of the hospital pharmacy, vaccination centre pharmacy, and clinical team. The patient-facing summary below reflects the instructions in the EMA Summary of Product Characteristics and FDA prescribing information; specific batches may carry slightly different labels, and the printed vial label and carton always take precedence over any general summary.

Spikevax JN.1 is supplied as a white to off-white dispersion for injection, 0.1 mg/mL, in multi-dose vials (typically 5 doses of 0.5 mL per vial, or 2.5 mL per vial, depending on presentation). The vials are shipped and stored under refrigerated or frozen conditions depending on the supply-chain stage.

Frozen Storage (Long-Term)

Unpunctured vials of Spikevax JN.1 should be stored frozen at −50 °C to −15 °C in the original carton, protected from light. In this state the product is stable up to the printed expiry date. During frozen storage, the vials should not be exposed to temperatures outside this range, and excursions should be documented and evaluated in accordance with cold-chain protocols.

Refrigerated Storage (Thawed, Unpunctured)

Once thawed, vials can be kept at refrigerator temperature (2 °C to 8 °C) and must then be used within 30 days. After this period, unused vials must be discarded. During this 30-day refrigerated storage period, the product must remain in its original carton and must not be refrozen.

Room Temperature (Prior to Use)

A vial removed from refrigeration may be brought to room temperature (up to 25 °C) before administration. Total time at room temperature before first puncture should not exceed the manufacturer's specification (typically up to 24 hours, but the exact figure is printed on the carton). Do not return a room-temperature vial to the refrigerator for subsequent long-term storage if this limit has been exceeded.

After Puncture (In Use)

Once the vial stopper has been punctured to withdraw the first dose, the vial can be held at 2–25 °C and must be used within 12 hours. Each dose withdrawn is prepared in a separate syringe. Vials must not be pooled, and doses must not be drawn from different vials into the same syringe. Any product remaining after 12 hours of first puncture must be discarded according to local biohazardous/pharmaceutical waste regulations.

Handling Precautions

• The vial should be swirled gently before each dose; it must not be shaken.
• The product must be visually inspected for particulate matter and discoloration; white to off-white product-related particulates are acceptable, but coloured particles, foreign matter, or clumping make the vial unusable.
• Vials must not be pooled; partial doses must not be combined from different vials.
• Dispose of used and expired vials according to local regulations for biohazardous pharmaceutical waste.
• Cold-chain breaches must be reported and evaluated before any affected vial is administered.

Patient and Caregiver Information

Patients and caregivers are not expected to store Spikevax JN.1. The vaccine is dispensed and administered in a clinical setting (vaccination centre, pharmacy, general practice, hospital). You will not receive vials to take home. If, exceptionally, a carer transports a prepared syringe for administration elsewhere, local guidelines governing the transport of prepared parenteral medicines apply and the 12-hour after-puncture limit must be respected. After the injection, no specific storage action is required on the patient's part; keep the vaccination record card or digital certificate in a safe place for future reference, and follow your vaccinator's advice on monitoring for any adverse events and on the timing of the next recommended dose.

What Does Spikevax JN.1 Contain?

Active Substance

The active substance is elasomeran, an engineered, single-stranded, 5'-capped messenger RNA (mRNA). The mRNA encodes the full-length, pre-fusion stabilized spike (S) glycoprotein of SARS-CoV-2 (Omicron sub-lineage JN.1). The sequence incorporates two proline substitutions (“2P”) that stabilize the antigenically important pre-fusion conformation of the spike protein, a modification that has been used across multiple authorized coronavirus vaccines. The uridine residues in the mRNA are replaced with N1-methylpseudouridine (m1Ψ), a nucleoside modification that reduces innate immune detection and enhances translation efficiency. One 0.5 mL dose contains 50 micrograms of elasomeran; one 0.25 mL paediatric dose contains 25 micrograms.

Lipid Nanoparticle Excipients

The mRNA is encapsulated in lipid nanoparticles (LNPs) composed of four lipid species that together protect the mRNA during storage and delivery:

• Ionizable cationic lipid (SM-102): [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate) — the principal lipid responsible for mRNA encapsulation and intracellular release at endosomal pH.
• PEG-lipid (PEG2000-DMG): 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, which forms the hydrophilic shell of the nanoparticle and stabilizes the particle in aqueous solution.
• Structural phospholipid (DSPC): 1,2-distearoyl-sn-glycero-3-phosphocholine, a helper lipid contributing to nanoparticle structure.
• Cholesterol: providing fluidity and structural integrity to the lipid bilayer.

Other Excipients

The aqueous phase of the suspension contains buffering and tonicity agents that maintain a physiological pH and osmolarity during storage and administration. These are:

• Tromethamine (Tris)
• Tromethamine hydrochloride
• Acetic acid
• Sodium acetate trihydrate
• Sucrose (as a cryoprotectant during frozen storage)
• Water for injections

Spikevax JN.1 does not contain any of the following: adjuvants (for example aluminium salts or squalene); preservatives (such as thiomersal); antibiotics (for example neomycin, streptomycin); egg or egg-derived proteins (therefore it is compatible with egg allergy); latex (the vial stopper is latex-free); gelatin or other animal-derived proteins; human blood or blood products; viral particles or live virus; DNA or genetic material that can integrate into the host genome.

Appearance and Presentation

Spikevax JN.1 is supplied as a white to off-white dispersion. Minor white or translucent product-related particulates may be visible and are acceptable; coloured particles, foreign matter, or clumping make the vial unusable. The most common presentations are a multi-dose vial containing 2.5 mL (five doses of 0.5 mL), although single-dose and other multi-dose presentations may exist depending on market. Each vial is packaged in a carton with a patient leaflet (for healthcare professional reference) and batch/lot information.

Allergy Considerations

Because Spikevax JN.1 is produced in a cell-free system and does not contain egg, latex, gelatin, or antibiotics, it is generally suitable for individuals with those specific allergies. The allergen of primary concern is polyethylene glycol (PEG), present as PEG2000-DMG in the lipid nanoparticle. Anaphylaxis to PEG or to polysorbate-containing products (due to cross-reactivity) is a contraindication to Spikevax JN.1 and warrants specialist allergy evaluation before any decision about alternative COVID-19 vaccines.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded in the patient's vaccination record and, where applicable, in the national immunization registry. This recording allows downstream pharmacovigilance signal detection, facilitates booster scheduling, and supports epidemiological monitoring of vaccine effectiveness in real-world settings.